Stockreport

Eupraxia Pharmaceuticals Reports Fourth Quarter 2025 Financial Results

Eupraxia Pharmaceuticals Inc.  (EPRX) 
PDF VICTORIA, British Columbia, March 12, 2026 (GLOBE NEWSWIRE) -- Eupraxia Pharmaceuticals Inc. (“Eupraxia” or the “Company”) (NASDAQ:EPRX) (TSX:EPRX), a clinical-stage b [Read more]